Organicell Regenerative Medicine Rebranding to ZEO ScientifiX

March 4, 2024 4:15 PM

Leading Therapeutics Research Company Begins New EraCommon Stock to trade on OTCQB under the symbol "ZEOX" commencing March 5, 2024FORT LAUDERDALE, FL / ACCESSWIRE / March 4, 2024 / ZEO ScientifiX, Inc. (OTCQB:ZEOX) (f/k/a Organicell Regenerative Medicine, Inc. - OTCQB: OCEL) today reported that the Financial Industry Regulatory Agency ("FINRA") completed the processing of the Company's Corporate Action Notification Form filed with respect to...

Read more

Adolore BioTherapeutics Announces Issuance of First U.S. Patent Covering CA8* Gene Therapies to Treat Chronic Pain

March 4, 2024 10:00 AM

Patent and CA8* gene therapy technology licensed by Adolore BioTherapeutics from the University of MiamiCompany advancing development of rdHSV-CA8* gene therapy for the treatment of chronic osteoarthritis (OA) knee pain toward an INDDELRAY BEACH, FL / ACCESSWIRE / March 4, 2024 / Adolore BioTherapeutics ("Adolore" or the "Company"), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain,...

Read more

Berlin Cures' BC 007 Targets Long COVID: Solid Phase II Trial Progress with Over 50% Patient Recruitment

March 4, 2024 6:20 AM

Berlin Cures, a clinical-stage biotechnology firm, advances innovative treatment aimed at combating Long COVID, currently impacting over 100 million people globally. Over 50% of patients in randomized placebo-controlled Phase-II-trial now recruited; no issues regarding safety observed. Berlin Cures innovative platform develops novel aptamer-based drugs to neutralize pathogenic functional autoantibodies, targeting diseases. BERLIN, GERMANY /...

Read more

AbTherx Announces Transition from Early Access to Commercialization of its Bispecific and Full Human Diversity Antibody Discovery Technologies

March 4, 2024 6:00 AM

Atlas™ Mice can now be evaluated by pharmaceutical and biotech companies and accessed through a network of preferred service providersMOUNTAIN VIEW, CA / ACCESSWIRE / March 4, 2024 / AbTherx, a biotechnology company with innovative technologies that enable and accelerate antibody discovery, today announced expanded commercialization of its bispecific and full human diversity antibody discovery technologies. After an initial successful launch...

Read more

MRES: M2Bio Sciences Provides Corporate Update

March 1, 2024 9:10 AM

CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / March 1, 2024 / Institute of Biomedical Research Corporation (OTC PINK:MRES) is pleased to provide further details of the sale to Real American Capital Corporation (OTC PINK:RLAB) of 100% ownership of the concept, business model, contacts and contracts that collectively can be used to establish a mixed martial arts league and are herein referred to as "M2MMA" (https://m2mma.com).The transaction was...

Read more

NovAccess Global Provides Business Updates and Announces Scheduling of Annual Meeting of Shareholders

March 1, 2024 9:00 AM

CLEVELAND, OH / ACCESSWIRE / March 1, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today provided an update on business developments, financing and the 2024 annual meeting.The previously disclosed $10.7 million financing transaction with Sumner Global LLC remains pending, as Sumner Global has not yet obtained the funding necessary to close the transaction. To provide...

Read more

enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

February 29, 2024 4:15 PM

$46.4 million cash and investments on hand sufficient to fund current operations, including multiple value driving milestones, through the end of 2025Topline efficacy data for VenoValve® U.S. pivotal trial to be presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024Continued progress toward launch of GLP study for enVVe® transcatheter-based replacement venous valveIRVINE, CA / ACCESSWIRE / February 29, 2024 / enVVeno...

Read more

Hemogenyx Pharmaceuticals PLC Announces Placing to Raise US$4.2 million

February 29, 2024 2:00 AM

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT IN, ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATIONS (EU) NO. 596/2014 WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UKMAR").MARKET SOUNDINGS WERE TAKEN IN...

Read more

Form Bio and Ginkgo Partner to Develop Industry-Leading Solutions for AAV Gene Therapy Design and Development

February 28, 2024 7:01 AM

Combined Solution Set Addresses Critical Hurdles in Bringing Gene Therapy Products to INDDALLAS, TX / ACCESSWIRE / February 28, 2024 / Form Bio, the breakthrough computational life sciences solutions provider, and Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, today announced a new partnership to provide a complete and holistic solution offering for AAV gene therapy design and development. The...

Read more

Year-end Report 2023

February 28, 2024 2:20 AM

STOCKHOLM, SWEDEN / ACCESSWIRE / February 28, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, February 28, 2024- Vicore Pharma Holding AB (STO:VICO) ("Vicore"), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), publishes the year-end report 2023.Important events during the fourth quarterIn October, Vicore announced the results from the Phase 1 study of C106. Further development of the...

Read more

Relief Therapeutics Renews CHF 50 million Share Subscription Facility

February 28, 2024 1:00 AM

3-year CHF 50 million capital commitment from GEMRelief advances strategic transformationGENEVA, SWITZERLAND / ACCESSWIRE / February 28, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced the renewal of its CHF 50 million Share Subscription Facility (SSF)...

Read more

Prolocor Announces $1.7 Million in Bridge Funding

February 27, 2024 9:00 AM

Green Park & Golf Ventures and Labcorp continue to demonstrate ongoing commitment to Prolocor initiatives.Funding will be used for ongoing clinical program and commercialization in 2024.PHILADELPHIA, PA / ACCESSWIRE / February 27, 2024 / Prolocor, Inc., a healthcare startup developing an innovative precision diagnostic test with the potential to predict the risk of thrombosis by quantifying FcγRIIa (pFCG test), today announced that they have...

Read more

Vicore to Present at Upcoming Investor Conferences

February 27, 2024 2:20 AM

STOCKHOLM, SE / ACCESSWIRE / February 27, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, February 27, 2024 - Vicore Pharma Holding AB (publ), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the following investor conferences:TD Cowen 44th Annual Health Care ConferenceLocation: Boston, MA.Presenter: Ahmed Mousa, CEOPresentation Date and Time: March 6...

Read more

ScaiPod: Revolutionizing Immuno-Oncology With Multi-Omics and AI at Scale

February 26, 2024 10:05 AM

BASEL, SWITZERLAND / ACCESSWIRE / February 26, 2024 / Scailyte is thrilled to announce ScaiPod, a moonshot initiative to solve some of the toughest clinical challenges in immuno-oncology. ScaiPod's mission is to fuel the development of a new generation of clinical biomarkers predictive for the response to immune checkpoint inhibitors (ICI) and thus to enable precision immuno-oncology. Additionally, it will unravel mechanistic insights related to...

Read more

The Selux PBC Separator With Selux AST System Receives FDA 510(k) Clearance for Rapid Antibiotic Susceptibility Testing Direct From Positive Blood Culture

February 26, 2024 9:30 AM

The Selux PBC Separator, part of the Next Generation Phenotyping (NGP) System, makes this the only FDA cleared, single-platform technology capable of delivering rapid AST results for both positive blood culture and isolated colonies.BOSTON, MA / ACCESSWIRE / February 26, 2024 / Selux Diagnostics, a biotech startup in Boston whose mission is to combat superbug infections and preserve the lifesaving power of antibiotics for future generations,...

Read more

MRES: M2Bio Sciences Introduces M2BioKids: A Pioneering Approach to Elevating Childhood Health and Development

February 23, 2024 9:20 AM

CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / February 23, 2024 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specializing in alternative plant-based cannabinoids, medical psilocybin, and cutting-edge mental health therapeutic research driven by artificial intelligence (AI), is pleased to announce the following updates:M2Bio Sciences proudly announces the launch of its...

Read more

MRES: M2Enviro 2023 Year-End Review and 2024 Looking Forward

February 22, 2024 9:15 AM

CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / February 22, 2024 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology,specializing in alternative plant-based cannabinoids, medical psilocybin, and cutting-edgemental health therapeutic research driven by artificial intelligence (AI), is pleased to sharethe following M2Enviro updates:M2Enviro, at the forefront of biotechnological...

Read more

BioInvent International AB Year-end Report January 1 - December 31, 2023

February 22, 2024 2:20 AM

LUND, SWEDEN / ACCESSWIRE / February 22, 2024 / BioInvent International (STO:BINV) "2023 was a landmark year for BioInvent with positive clinical readouts from three Phase 1/2 programs. These data, supported by validating partnerships, a strong cash position and solid investor base, set BioInvent up to have a breakout year in 2024, fueled by expectations for substantial clinical progress across our pipeline." - Martin Welschof, CEO of...

Read more

Gerresheimer Decisively Continues on Profitable Growth Course in Financial Year 2023

February 22, 2024 1:20 AM

Organic revenue growth in 2023: +10.4%Organic adjusted EBITDA growth in 2023: +17.5%Favorable product mix boosts profitabilityHigh order backlog and global capacity expansion secure profitable growth for the years aheadDUSSELDORF, GERMANY / ACCESSWIRE / February 22, 2024 / Gerresheimer, an innovative system and solution provider and a global partner for the pharma, biotech and cosmetic industries, decisively continued on its profitable growth...

Read more

IMBIOTECHNOLOGIES Signs Supply Agreement Embol Experts

February 21, 2024 10:25 AM

EDMONTON, AB / ACCESSWIRE / February 21, 2024 / IMBiotechnologies Ltd. ("IMBiotechnologies") is pleased to announce the signing of a supply agreement with Embol Experts, LLC ("Embol Experts"), one of the largest group purchasing organizations (GPOs) in the US, supplying office-based laboratory (OBL) and ambulatory surgical center (ASC) clinics focused on minimally-invasive procedures."We are excited to be working with IMBiotechnologies as their...

Read more